| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
(Z)-Guggulsterone, the cis-isomer of Guggulsterone, is a naturally occuring phytosteroid isolated from the resin of the guggul plant, Commiphora mukul. In humans, it functions as an antagonist of the farnesoid X receptor (FXR). (Z)-Guggulsterone, a component of the Indian Ayurvedic medicinal plant Commiphora mukul, induces apoptosis in human prostate cancer cells, thereby inhibiting their growth. Z-guggulsterone blocks the VEGF–VEGF-R2–Akt signaling axis, which prevents angiogenesis.
| Targets |
VEGF-R2
|
|---|---|
| ln Vitro |
In HUVEC, (Z)-GugguLsterone (10, 20 μM; 24 or 48 hours) lowers the levels of VEGF-R2 protein [1]. Through FXR-mediated ACE2 modulation, (Z)-Guggulsterone (10 μM; 24) decreases primary airways, disturbs ACE2 and SHP levels in organoids, and lessens SARS-CoV-2 infection in many cell types [2].
The z-guggulsterone treatment inhibited capillary-like tube formation (in vitro neovascularization) by human umbilical vein endothelial cells (HUVEC) and migration by HUVEC and DU145 human prostate cancer cells in a concentration- and time-dependent manner. The z- and E-isomers of guggulsterone seemed equipotent as inhibitors of HUVEC tube formation[1]. |
| ln Vivo |
(Z)-Guggulsterone (silica; 1 mg; 5 x weekly) dramatically lowers wet weight and tumor volume [1].
Oral gavage of 1 mg z-guggulsterone/d (five times/wk) to male nude mice inhibited in vivo angiogenesis in DU145-Matrigel plug assay as evidenced by a statistically significant decrease in tumor burden, microvessel area (staining for angiogenic markers factor VIII and CD31), and VEGF-R2 protein expression. In conclusion, the present study reveals that z-guggulsterone inhibits angiogenesis by suppressing the VEGF-VEGF-R2-Akt signaling axis. Together, our results provide compelling rationale for further preclinical and clinical investigation of z-guggulsterone for its efficacy against prostate cancer[1]. |
| Enzyme Assay |
The z-guggulsterone-mediated inhibition of angiogenesis in vitro correlated with the suppression of secretion of proangiogenic growth factors [e.g., vascular endothelial growth factor (VEGF) and granulocyte colony-stimulating factor], down-regulation of VEGF receptor 2 (VEGF-R2) protein level, and inactivation of Akt. The z-guggulsterone-mediated suppression of DU145 cell migration was increased by knockdown of VEGF-R2 protein level. Ectopic expression of constitutively active Akt in DU145 cells conferred protection against z-guggulsterone-mediated inhibition of cell migration[3].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: Vascular Endothelial Growth Factor (VEGF) Tested Concentrations: 10, 20 μM Incubation Duration: 24 or 48 hrs (hours) Experimental Results: Caused a decrease in VEGF-R2 protein levels in HUVEC. |
| Animal Protocol |
Animal/Disease Models: Male nude mice (5-6 weeks old) were subcutaneously (sc) (sc) implanted with Matrigel plugs containing DU145 cells.
Doses: 1 mg. Route of Administration: po (po (oral gavage)) 5 times a week. Experimental Results: Resulting in statistically significant tumor volume and wet tumor weight. reduce. |
| References | |
| Additional Infomation |
Guggulsterone is a 3-hydroxy steroid. It has a role as an androgen.
Guggulsterone has been reported in Commiphora mukul and Commiphora wightii with data available. |
| Molecular Formula |
C21H28O2
|
|---|---|
| Molecular Weight |
312.45
|
| Exact Mass |
312.208
|
| Elemental Analysis |
C, 80.73; H, 9.03; O, 10.24
|
| CAS # |
39025-23-5
|
| Related CAS # |
39025-23-5
|
| PubChem CID |
6450278
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
463.3±45.0 °C at 760 mmHg
|
| Melting Point |
188-190°
|
| Flash Point |
172.3±25.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
3.65
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
640
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C/C=C/1\C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
|
| InChi Key |
WDXRGPWQVHZTQJ-OSJVMJFVSA-N
|
| InChi Code |
InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1
|
| Chemical Name |
(8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione
|
| Synonyms |
Z-Guggulsterone; (Z)-Guggulsterone; Z-Guggulsterone; Guggulsterone; 39025-23-5; 95975-55-6; Guggulsterones Z; Cis-Guggulsterone; Guggulsterone E&Z; (Z)-Guggulsterone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 5~10 mg/mL (16.0~32.0 mM)
Ethanol: ~2 mg/mL (~6.4 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 10 mg/mL (32.01 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2005 mL | 16.0026 mL | 32.0051 mL | |
| 5 mM | 0.6401 mL | 3.2005 mL | 6.4010 mL | |
| 10 mM | 0.3201 mL | 1.6003 mL | 3.2005 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
